Why the study?
Does the use of sirolimus-eluting stents compared to paclitaxel-eluting stents improve clinical outcomes and reduce stent thrombosis in patients with STEMI undergoing primary PCI?
Does the use of sirolimus-eluting stents compared to paclitaxel-eluting stents improve clinical outcomes and reduce stent thrombosis in patients with STEMI undergoing primary PCI?
In a real-world STEMI cohort, sirolimus-eluting and paclitaxel-eluting stents demonstrated similar 2-year rates of major adverse cardiac events and stent thrombosis, though overall stent thrombosis rates were notably high.
Answers are grounded in this paper and cite their sources.
No significant MACE or thrombosis differences between sirolimus- and paclitaxel-eluting stents in STEMI; leaves open optimal first-generation DES selection.
It has been shown that drug-eluting stents (DESs) significantly reduce restenosis rate when compared with bare-metal stents in a broad range of patients with coronary artery disease. However, current data are limited about the efficacy of different DESs in treatment of ST segment elevation myocardial infarction (STEMI). The aim of this study was to compare the effectiveness and safety of sirolimus-eluting stents (SESs) with paclitaxel-eluting stents (PESs) in primary percutaneous coronary intervention. We retrospectively examined 127 STEMI patients who underwent primary percutaneous coronary intervention. PES group consisted of 79 patients and SES group consisted of 48 patients. Patients were analyzed for major adverse cardiac events (MACE) and stent thrombosis (ST). The mean follow-up period was 2 years. The mean age was 53 ± 11 years in the SES group and 59 ± 11 years in the PES group (p = 0.03). Baseline and procedural characteristics were similar in the two groups except stent lengths, which was longer in the SES group. Two-year MACE rates were 8.3% in the SES group and 16.4% in the PES group (p = 0.28). Rates for ST for SES and PES groups were as follows: early ST was 2.08 versus 2.53%; late ST was 2.08 versus 2.53%; and very late ST was 2.08 versus 2.53% (p > 0.05). There were no statistically significant differences in MACE and ST rates between the SES and PES groups in the 2-year follow-up period. High ST rates detected in our study need to be clarified with future prospective and randomized clinical trials.
No takes yet. Share an insight, caveat, or question.
Erdim et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: